Immunotherapy against several tumors including neuronal and brain tumors
| Title: | Immunotherapy against several tumors including neuronal and brain tumors |
|---|---|
| Patent Number: | 8,119,139 |
| Publication Date: | February 21, 2012 |
| Appl. No: | 12/571776 |
| Application Filed: | October 01, 2009 |
| Abstract: | The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. |
| Inventors: | Weinschenk, Toni (Aichwald, DE); Schoor, Oliver (Tubingen, DE); Trautwein, Claudia (Wuelfrath, DE); Hilf, Norbert (Kirchentellinsfurt, DE); Walter, Steffen (Reutlingen, DE); Singh, Harpreet (Tübingen, DE) |
| Assignees: | Immatics Biotechnologies GmbH (Tubingen, DE) |
| Claim: | 1. A peptide consisting of the amino acid sequence of SEQ ID NO: 4, or a pharmaceutically acceptable salt thereof. |
| Claim: | 2. A fusion protein comprising the peptide of SEQ ID NO: 4 adjoined at the N-terminus and/or the C-terminus by one or more heterologous peptides, or a pharmaceutically acceptable salt thereof. |
| Claim: | 3. The fusion protein of claim 2 , wherein said one or more heterologous peptides is a carrier protein selected from keyhole limpet haemocyanin (KLH) and mannan. |
| Claim: | 4. The fusion protein of claim 2 , wherein the fusion protein maintains an ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or II, so as to be capable of stimulating CD4+ and/or CD8+ T cells specific. |
| Claim: | 5. The fusion protein of claim 2 , wherein said fusion protein has an overall length of between 10 and 100 amino acids. |
| Claim: | 6. The fusion protein of claim 2 , wherein the heterologus peptide comprises the 80 N-terminal amino acids of the HLA-DR antigen-associated invariant chain, Ii. |
| Claim: | 7. An acylated peptide consisting of SEQ ID NO: 4 or a pharmaceutically acceptable salt thereof. |
| Claim: | 8. A pegylated peptide consisting of SEQ ID NO: 4 or a pharmaceutically acceptable salt thereof. |
| Claim: | 9. A composition comprising a peptide of claim 1 or pharmaceutically acceptable salt thereof, and a pharmaceutically a pharmaceutically acceptable carrier. |
| Claim: | 10. A composition comprising a fusion protein of claim 2 or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. |
| Claim: | 11. A composition comprising an acylated peptide of claim 7 or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. |
| Claim: | 12. A composition comprising a pegylated peptide of claim 8 or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. |
| Claim: | 13. A method of inducing an immune response in a subject, the method comprising administering to the subject a peptide of claim 1 or a pharmaceutically acceptable salt thereof. |
| Claim: | 14. A method of inducing an immune response in a subject, the method comprising administering to the subject a fusion protein of claim 2 or a pharmaceutically acceptable salt thereof. |
| Claim: | 15. A method of inducing an immune response in a subject, the method comprising administering to the subject an acylated peptide of claim 7 or a pharmaceutically acceptable salt thereof. |
| Claim: | 16. A method of inducing an immune response in a subject, the method comprising administering to the subject a pegylated peptide of claim 8 or a pharmaceutically acceptable salt thereof. |
| Claim: | 17. A kit comprising: (a) container that contains a composition containing, in solution and/or in lyophilized form, a peptide of claim 1 or the fusion protein of claim 2 ; (b) optionally, a second container comprising a diluent and/or reconstituting solution; (c) optionally, at least one additional peptide consisting of an amino acid sequence selected from SEQ ID NOs: 1-3 and 5-30; and (d) optionally, instructions for (i) use of the diluent and/or (ii) reconstitution and/or use of a lyophilized formulation. |
| Claim: | 18. The kit according to claim 17 , further comprising one or more of (e) a buffer, (f) a diluent, (g) a filter, (h) a needle, and (i) a syringe. |
| Current U.S. Class: | 4241/851 |
| Patent References Cited: | 6589642 July 2003 Miller et al. 2002/0090672 July 2002 Rosen et al. 2003/0175733 September 2003 Kirst et al. 0570188 June 2007 2 111 867 April 2009 WO0155368 August 2001 02/20036 March 2002 02/46767 June 2002 02/074237 September 2002 03/045998 June 2003 2004/015390 February 2004 2005/116051 December 2005 2007072505 June 2007 2007/150077 December 2007 2008/109757 September 2008 |
| Other References: | Gunther et al. “Glioblastoma-derived stem cell-enriched cultures from distinct subgroups according to molecular and phenotypic criteria,” Oncogene (2008) 27, pp. 2897-2909 (XP-002557755). cited by other Suzuki et al., “Genetic analysis of human glioblastomas using a genomic microarray system,” Brain Tumor Pathol (2004) 21, pp. 27-34 (XP-002557756). cited by other Shibahara et al., “Podoplanin is expressed in subsets of tumors of the central nervous system,” Virchows Arch (2006) 448, pp. 493-499 (XP-002557757). cited by other International Journal of Cancer. Journal International DU Cancer May 18, 1998, vol. 76, No. 4, pp. 451-458, XP002572958 ISSN:0020-7136. cited by other Gary S C et al. “cDNA Cloning, chromosomal localization, and expression analysis of human BEHAB/brevican, a brain specific proteoglycan regulated during cortical development and in glioma” Gene, Elsevier, Amsterdam, NL, vol. 256, No. 1-2, Oct. 3, 2000, pp. 139-147, XP004238399 ISSN:0378-1119. cited by other International Preliminary Report on Patentability dated Apr. 5, 2011; Written Opinion dated dated Apr. 1, 2011. cited by other Extended European Search Report, EP 08 01 7921, Dec. 14, 2009 (15 pages). cited by other Gunther et al., “Glioblastoma-derived stem cell-enriched cultures from distinct subgroups according to molecular and phenotypic criteria,” Oncogene (2008) 27, pp. 2897-2909 (XP-002557755). cited by other Suzuki et al., “Genetic analysis of human glioblastomas using a genomic microarray system,” Brain Tumor Pathol (2004) 21, pp. 27-34 (XP-002557756). cited by other Shibahara et al., “Podoplanin is expressed in subsets of tumors of the central nervous system,” Virchows Arch (2006) 448, pp. 493-499 (XP-002557757). cited by other International Journal of Cancer. Journal International DU Cancer May 18, 1998, vol. 76, No. 4, pp. 451-458, XP002572958 ISSN:0020-7136. cited by other Gary S C et al. “cDNA Cloning, chromosomal localization, and expression analysis of human BEHAB/brevican, a brain specific proteoglycan regulated during cortical development and in glioma” Gene, Elsevier, Amsterdam, NL, vol. 256, No. 1-2, Oct. 3, 2000, pp. 139-147, XP004238399 ISSN:0378-1119. cited by other International Preliminary Report on Patentability dated Apr. 5, 2011; Written Opinion dated dated Apr. 1, 2011. cited by other International Search Report dated Mar. 30, 2010; International Application No. PCT/EP2009/006980. cited by other Search Report for PCT/EP2008/006980 dated Sep. 26, 2008. cited by other |
| Primary Examiner: | Rawlings, Stephen |
| Attorney, Agent or Firm: | Baker Donelson Bearman, Caldwell & Berkowitz, PC |
| Accession Number: | edspgr.08119139 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|